News

The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.

NALIRIFOX improved overall survival and progression-free survival in patients with metastatic pancreatic ductal adenocarcinoma.

A study of patients with relapsed/refractory diffuse large B-cell lymphoma has showed that continuous administration of PD-1 inhibitors as a maintenance treatment may be feasible to maintain the efficacy of anti-CD19-CAR T cells.

Robert L. Ferris, MD, PhD, reflects on the status of telehealth in oncology and patient care following the COVID-19 pandemic.

Development of PYX-201 in advanced solid tumors is underway, and the drug has grabbed the FDA's attend with a phase 1 study in pancreatic cancer.

Jeffrey R. Schriber, MD, FRCP, discusses some of the available treatment options for patients with multiple myeloma and how the treatment landscape has evolved over time.

ACR-368 generated deep and durable responses across several phase 2 studies. The agent has now been granted fast track designations for patients with platinum-resistant ovarian cancer and endometrial cancer.

FDA approval has not been granted to N-803 for the treatment of Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ.

Real-world evidence support the use of venetoclax-based regimens for patients with chronic lymphocytic leukemia based the consistent efficacy shown between the real-world and clinical trial data.

An analysis of Medicare patients with follicular lymphoma revealed which characteristics correlated with overall survival.

John Nakayama, MD, discusses what the evolution of endometrial cancer treatment has looked like in recent years.

Emerging data demonstrate the potential of these drugs to optimize survival, preserve quality of life, and even spare patients a radical cystectomy.

An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.

Significant differences in the incidence of genitourinary events, depression, and ischemic and thrombotic events were observed based on race among patients with prostate cancer after receiving androgen deprivation therapy.

Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.

The new DNA methylation-based PDACatch assay has received a breakthrough device designation from the FDA to detect patients at high-risk for pancreatic adenocarcinoma.

Looking at real-world data, researchers identified a large increase of biomarker testing for patients with early-stage non–small cell lung cancer, which indicates a continuing trend toward personalized treatment.

According to findings from an integrated BIM, single treatment with selpercatinib had a little impact on third-party payers’ formulary budgets for patients with RET-altered solid tumors.

Findings from a survey found that many physicians used new strategies to manage their patients during the COVID-19 pandemic, some of which, such as the use of telehealth, are expected to continue into the future.

New results from ORIENT-31 show a sustained progression-free survival benefit and overall survival improvement trend in patients with EGFR-mutant non–small cell lung cancer who failed a tyrosine kinase inhibitor previously.

Two genetically engineered gamma-delta T-cell therapies, INB-400 and INB-410, have been granted an orphan drug designation from the FDA for numerous types of malignant glioma.

A study looked into what drives patient preference for treatment with certain BRAF/MEK inhibitors for BRAF V600E/K-mutant melanoma.

Treatment with lurbinectedin is cost-effective as a second-line treatment for patients with metastatic small cell lung cancer who have had disease progression on or after platinum-based chemotherapy.

Ashish Saxena, MD, explains the outcomes of the addition of immune checkpoint blockade to standard chemotherapy for patients with metastatic small cell lung cancer.

Adjuvant chemotherapy did not lead to survival improvements vs standard chemoradiotherapy alone in patients with locally advanced cervical cancer and resulted in more severe adverse events, according to OUTBACK trial data.

In an interview with Targeted Oncology, Adam J. Olszewski, MD, discussed mosunetuzumab and the rationale and findings of this phase 1b/2 study assessing the agent in elderly patients with diffuse large B-cell lymphoma.

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck did not derive an overall response rate benefit with nivolumab and ipilimumab vs nivolumab alone.

The FoundationOne® Liquid CDx has been granted approval by the FDA as a companion diagnostic for mobocertinib for patients with locally advanced or metastatic non–small cell lung cancer harboring an EGFR exon 20 insertion mutation.

Results from the phase 3 QuANTUM-First study create a position for quizartinib plus chemotherapy in the FLT3-ITD-positive acute myeloid leukemia armamentarium.

Yann-Alexandre Vano, MD, explains some of the findings from the phase 2 BIONIKK trial which evaluated nivolumab and ipilimumab in metastatic renal cell carcinoma.